Background:
DJS-AbbVie is an AbbVie R&D hub located in Oxford, created following AbbVie’s acquisition in 2022 of DJS Antibodies. As part of AbbVie, we aim to develop new medicines that improve the lives of patients with immunological diseases.
To achieve this, we have built and are now expanding an R&D presence in Oxford that integrates drug design, human-centric biology and mechanistic clinical testing. We have discovered and developed multiple novel pipeline candidates in immunological diseases through our onsite capabilities in antibody discovery and translational biology. We also act as a UK and European hub for the wider AbbVie R&D organisation, uncovering novel biology and advancing late-stage assets to the clinic through collaboration with top-tier acad...